Role of Cell Cycle Regulators in Lung Carcinogenesis

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2010 Feb 9

PMID 20139697

Citations 48

Authors

Beatrice Eymin

Sylvie Gazzeri

Affiliations

Soon will be listed here.

Abstract

Cellular division is an ordered, tightly regulated process involving multiple checkpoints that assess extracellular growth signals, cell size and DNA integrity. Progression throughout the cell cycle is based on the activation of different CDK-cyclin complexes that prevent cells from entering into a new phase until thay have successfully complete the previous one. In addition, a series of cell cycle checkpoints are designed to preserve genome integrity and chromosomal stability. Neoplastic lung cells develop the ability to bypass several of these checkpoints, and tumor cell proliferation is frequently associated with genetic or epigenetic alterations in key regulators of the cell cycle. The goal of this review is to summarize the knowledge about the dysregulation of major cell cycle regulators in lung cancer pathogenesis and to discuss the use of these proteins as targets for therapeutic intervention.

Citing Articles

The potential of the South African plant Tulbaghia Violacea Harv for the treatment of triple negative breast cancer.

Alaouna M, Molefi T, Khanyile R, Chauke-Malinga N, Chatziioannou A, Luvhengo T Sci Rep. 2025; 15(1):5737.

PMID: 39962120 PMC: 11832780. DOI: 10.1038/s41598-025-88417-2.

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer.

Roggero C, Ghosh A, Devineni A, Ma S, Blatt E, Raj G Transl Oncol. 2024; 52():102231.

PMID: 39662449 PMC: 11683282. DOI: 10.1016/j.tranon.2024.102231.

Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells.

Nam A, Joo S, Khong Q, Park J, Lee N, Lee S Sci Rep. 2024; 14(1):20820.

PMID: 39242647 PMC: 11379681. DOI: 10.1038/s41598-024-70823-7.

Cross-attention enables deep learning on limited omics-imaging-clinical data of 130 lung cancer patients.

Verma S, Magazzu G, Eftekhari N, Lou T, Gilhespy A, Occhipinti A Cell Rep Methods. 2024; 4(7):100817.

PMID: 38981473 PMC: 11294841. DOI: 10.1016/j.crmeth.2024.100817.

Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma.

Sun Y, Li S, Liu C, Pan Y, Xiao Y Aging (Albany NY). 2024; 16(10):8747-8771.

PMID: 38771129 PMC: 11164517. DOI: 10.18632/aging.205837.

References

Pei X, Bai F, Smith M, Xiong Y . p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. Cancer Res. 2007; 67(7):3162-70. DOI: 10.1158/0008-5472.CAN-06-4517. View

Cooper W, Kohonen-Corish M, McCaughan B, Kennedy C, Sutherland R, Lee C . Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 2009; 55(1):28-36. DOI: 10.1111/j.1365-2559.2009.03331.x. View

Hayashi H, Ogawa N, Ishiwa N, Yazawa T, Inayama Y, Ito T . High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer. 2001; 34(1):59-65. DOI: 10.1016/s0169-5002(01)00211-2. View

Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D . DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res. 2006; 66(22):11062-9. DOI: 10.1158/0008-5472.CAN-06-1039. View

Strebhardt K, Ullrich A . Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006; 6(4):321-30. DOI: 10.1038/nrc1841. View

Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli V . Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A. 2007; 104(10):4089-94. PMC: 1820713. DOI: 10.1073/pnas.0606537104. View

Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H . p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998; 58(5):1042-7. View

Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S . Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res. 2000; 6(1):11-6. View

Kosacka M, Piesiak P, Porebska I, Korzeniewska A, Dyla T, Jankowska R . Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA. In Vivo. 2009; 23(4):519-25. View

10.

Chaussade L, Eymin B, Brambilla E, Gazzeri S . Expression of p15 and p15.5 products in neuroendocrine lung tumours: relationship with p15(INK4b) methylation status. Oncogene. 2001; 20(45):6587-96. DOI: 10.1038/sj.onc.1204798. View

11.

Singhal S, Vachani A, Antin-Ozerkis D, Kaiser L, Albelda S . Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005; 11(11):3974-86. DOI: 10.1158/1078-0432.CCR-04-2661. View

12.

Rusin M, Okamoto A, Chorazy M, Czyzewski K, Harasim J, Spillare E . Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer. 1996; 65(6):734-9. DOI: 10.1002/(SICI)1097-0215(19960315)65:6<734::AID-IJC4>3.0.CO;2-#. View

13.

Singhal S, Amin K, Kruklitis R, DeLong P, Friscia M, Litzky L . Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther. 2003; 2(3):291-8. DOI: 10.4161/cbt.2.3.399. View

14.

Hickson I, Zhao Y, Richardson C, Green S, Martin N, Orr A . Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004; 64(24):9152-9. DOI: 10.1158/0008-5472.CAN-04-2727. View

15.

Gu J, Gong Y, Huang M, Lu C, Spitz M, Wu X . Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 2006; 28(2):350-5. DOI: 10.1093/carcin/bgl149. View

16.

Shapiro G, Edwards C, Kobzik L, Godleski J, Richards W, Sugarbaker D . Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55(3):505-9. View

17.

Xiao S, Li D, Corson J, Vijg J, Fletcher J . Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 1995; 55(14):2968-71. View

18.

Packenham J, Taylor J, White C, Anna C, Barrett J, Devereux T . Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res. 1995; 1(7):687-90. View

19.

Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H . The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004; 15(2):252-6. DOI: 10.1093/annonc/mdh073. View

20.

Harbour J, Lai S, Whang-Peng J, Gazdar A, Minna J, Kaye F . Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988; 241(4863):353-7. PMC: 5480895. DOI: 10.1126/science.2838909. View